Clene Nanomedicine Presents New Neuroprotection Data in Parkinson's Disease with Lead
Clene Nanomedicine Presents New Neuroprotection Data in Parkinson's Disease with Lead Nanocatalytic Therapeutic, CNM-Au8
Clene Nanomedicine Presents New Neuroprotection Data in Parkinson's Disease with Lead Nanocatalytic Therapeutic, CNM-Au8 Although targeting Parkinson's, new product approved for consideration in Amyotrophic Lateral Sclerosis and other neurological disorders. |
All times are GMT -5. The time now is 11:59 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.